Patient advocates and industry groups praised Virginia Gov. Abigail Spanberger’s veto of Prescription Drug Affordability Board (PDAB) legislation (HB 483 and SB 271). Advocates argued that similar PDAB efforts failed to lower costs while creating uncertainty around patient access to medicines. BIO also commended the veto, warning the bill would have imposed arbitrary price controls and could harm Virginia’s innovation economy. The statement referenced repeated legislative attempts over multiple years, with prior PDAB bills also being vetoed.